Clinical Pearls for the Treatment of AD
Expert dermatologists share clinical pearls for providers treating patients with AD, and discuss the future of AD treatment.
EP: 1.Intro to Janus Kinase (JAK) Inhibitors for Treatment of Atopic Dermatitis (AD)
EP: 2.Targeting the JAK-STAT Pathway in AD
EP: 3.Differentiating JAK Inhibitors From Other Therapies in AD
EP: 4.Indications and Efficacy of JAK Inhibitors for AD
EP: 5.Safety of JAK Inhibitors Approved for AD Treatment
EP: 6.Boxed Warnings for JAK Inhibitors in AD
EP: 7.Contraindications for Use of JAK Inhibitors in AD
EP: 8.Treatment Selection of JAK Inhibitors for the Management of AD
EP: 9.Utilizing JAK Inhibitors in Clinical Practice
EP: 10.Access to JAK Inhibitors in AD
EP: 11.Clinical Pearls for the Treatment of AD
This is a video synopsis/summary of a panel discussion involving Christopher Bunick, MD, PhD; Peter Lio, MD; Lisa Swanson, MD, PhD; and Alexandra Golant, MD.
Dr Swanson shares a clinical pearl emphasizing the importance of discussing with patients not only the potential side effects of medications but also the side effects of inadequately controlling atopic dermatitis (AD). She stresses the impact of uncontrolled AD on a patient's quality of life and well-being, highlighting how patients may not fully realize the extent of their suffering until effective treatment is administered. Dr Swanson suggests considering the metaphor of a slowly-heating bathtub to illustrate how AD can gradually worsen, affecting patients without them being fully aware.
Dr Golant adds to the discussion by focusing on severity score measures and the shift towards emphasizing quality of life. She suggests initiating systemic medications, including JAK inhibitors, based on the impact of AD on a patient's quality of life rather than solely relying on severity scores. The conversation also touches on the significance of recording accurate itch scores, connecting them to a tremendous difference in quality of life.
The clinical pearl from another colleague involves emphasizing patient compliance with JAK inhibitors. A patient's experience of rapid itch relief, akin to a light switch, underscores the importance of consistent medication adherence. Dr Swanson expresses enthusiasm about the future of AD management, anticipating advancements such as IL-31 inhibitors, additional IL-13 inhibitors, and non-steroidal topical medicines, reflecting the exciting prospect of a golden age in the treatment of atopic dermatitis.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.
